Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Metamfetaminisomerfarmakologi hos mennesker

30. oktober 2026 opdateret af: University of Wisconsin, Madison

The Low-Down on Methamphetamine isomers: Prevalens and Pharmacology in Humans

This study is being done to understand the metabolism and impairment profile of methamphetamine (meth). Meth exists as two chemical structures that are mirror images of each other: R-meth and S-meth. S-meth is a strong central nervous system stimulant and used to treat attention deficit disorder (ADD). R-meth is not a strong central nervous system stimulant and is available over-the-counter in nasal decongestant sprays.17 healthy participants will be enrolled for 3 study visits and on study for up to 12 weeks.

Studieoversigt

Detaljeret beskrivelse

Double-blind crossover study design. Healthy volunteers will attend three study drug administration visits, at least 7 days apart, in which methamphetamine isomer pharmacology will be assessed following intravenous administration of (1) S-(+)-methamphetamine, (2) R(-)-methamphetamine, or (3) a (1:1) racemic mixture of R-(-)- and S-(+)-methamphetamine. The order of these interventions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick, oral fluid collections, and pooled urine specimens.

Primary Objective

  • Characterize the pharmacokinetics of acute S-(+)-methamphetamine administration.
  • Characterize the pharmacokinetics of acute R-(-)-methamphetamine administration.
  • Characterize the pharmacokinetics of acute racemic (1:1) R-(-)- and S-(+)-methamphetamine administration.

Secondary Objectives

  • Assess for evidence of stereo-selective metabolic pathways.
  • Assess for evidence of subjective, cognitive, or physiological effects from acute R-(-)-methamphetamine administration.
  • Assess for evidence of more than additive effects when administering racemic methamphetamine.

Correlative Objectives

  • Compare biological methamphetamine and metabolite concentrations in surveyed biological matrices (i.e., plasma, whole blood, oral fluid, dried capillary blood spots, and urine) over time.
  • Compare cognitive and subjective effects of acute S-(+)-methamphetamine, R-(-)-methamphetamine, and racemic methamphetamine administration.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

17

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Wisconsin
      • Madison, Wisconsin, Forenede Stater, 53705
        • University of Wisconsin

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

21 år til 64 år (Voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Good mental health as determined by self-reported responses to the Psychopathology Screener
  • Absence of any major cardiac, neurologic, psychiatric, oncologic, endocrine, metabolic, renal, or hepatic disease as determined by self-reported responses to the Medical History Screener
  • English-speaking (able to provide consent and complete questionnaires)
  • Written Informed Consent

Exclusion Criteria:

  • Any serious prior adverse response to sympathomimetic agents or amphetamine analogs
  • History of or current substance use disorder as determined by self-reported responses to the Internalizing, Externalizing, and Substance Use Disorder Screener
  • Pregnancy or lactation (pregnancy test, if needed)
  • Use of medications that may impact cognition or metabolism (e.g., mood stabilizers, sedatives)
  • Dependent on prohibited concomitant therapy that cannot be withheld for 48 hours prior to and during study visits.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: S-Meth, R-Meth, Racemic Isomer

First visit: Administer S-Meth, then at least 7 days later Second visit: Administer R-Meth, then at least 7 days later Third visit: Administer (1:1) racemic methamphetamine

15 mg

Andre navne:
  • S-Meth

15 mg

Andre navne:
  • R-Meth

15 mg R-Meth + 15 mg S-Meth

Eksperimentel: R-Meth, Racemic Isomer, S-Meth

First visit: Administer R-Meth, then at least 7 days later Second visit: Administer (1:1) racemic methamphetamine, then at least 7 days later Third visit: Administer S-Meth

15 mg

Andre navne:
  • S-Meth

15 mg

Andre navne:
  • R-Meth

15 mg R-Meth + 15 mg S-Meth

Eksperimentel: Racemic Isomer, S-Meth, R-Meth

First visit: Administer (1:1) racemic methamphetamine, then at least 7 days later Second visit: Administer S-Meth, then at least 7 days later Third visit: Administer R-Meth

15 mg

Andre navne:
  • S-Meth

15 mg

Andre navne:
  • R-Meth

15 mg R-Meth + 15 mg S-Meth

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Peak concentration (Cmax)
Tidsramme: pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48 hours

The pharmacokinetic analysis relies on observed drug and metabolite concentration measurements over time and across biological matrices (plasma, whole blood, dried capillary spots, oral fluid, urine) included in this study.

pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48 hours
Area under the concentration versus time curve (AUC)
Tidsramme: pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48 hours

The pharmacokinetic analysis relies on observed drug and metabolite concentration measurements over time and across biological matrices (plasma, whole blood, dried capillary spots, oral fluid, urine) included in this study.

pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48 hours

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Cognitive Effects: Divided Attention Task (DAT)
Tidsramme: Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)

The DAT requires participants track a moving stimulus on a computer screen while simultaneously monitoring numbers located in the corners of the screen. Participants must respond to target numbers as they appear, and the task quantifies mean distance of the mouse cursor from the center of the target stimulus.

Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
Cognitive Effects: Digital Symbol Substitution Task (DSST)
Tidsramme: Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)

The DSST asks participants to recreate patterns of various shapes presented on a computer screen using the keyboard. The total number of correct patterns are recorded within 90 seconds.

Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
Cognitive Effects: Paced Serial Addition Task (PASAT)
Tidsramme: Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)

The PASAT has participants view a string of single-digit numbers and calculate the sum of the two most recently presented numbers. The total number of correct trials out of 90 will be recorded.

Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
Subjective Effects: Drug Effect Questionnaire (DEQ)
Tidsramme: Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)

Subjective current general effects will be measured by asking the participant to rate if they feel the drug effect, if they like/dislike the drug effect, if they feel high, and if they would like more of the drug. Effects will be measured on a scale from "not at all" anchored at 0 to "extremely" at 100.

Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
Subjective Effects: Number of Participants Who Answer 'True' for Amphetamine-specific questions
Tidsramme: Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)

Participants will be asked 11 amphetamine-specific questions including feelings of pleasantness, excitability, memory, emptiness, body tingling, weird feeling, patience, and mental sharpness. Results are measured as either "true" (experiencing the specific state) or "false" (not experiencing the specific state). Number of participants who answered 'True' is reported here

Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Heather K Barkholtz, PhD, University of Wisconsin, Madison
  • Ledende efterforsker: David Leinweber, MD, University of Wisconsin, Madison

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. januar 2027

Primær færdiggørelse (Anslået)

1. januar 2029

Studieafslutning (Anslået)

1. januar 2029

Datoer for studieregistrering

Først indsendt

9. december 2024

Først indsendt, der opfyldte QC-kriterier

18. december 2024

Først opslået (Faktiske)

24. december 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

30. oktober 2026

Sidst verificeret

1. august 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2024-1164
  • A523000 (Anden identifikator: UW Madison)
  • Protocol Version 2/12/25 (Anden identifikator: UW Madison)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner